Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0917816 (mental retardation)
 15,867 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Neuroleptic malignant syndrome (NMS) is an uncommon but serious adverse reaction to neuroleptic drugs. Clinically, it resembles malignant hyperthermia, a pharmacogenetic disorder of anesthesiology. Inv dup(15) is a rare but underrecognized cause of mental retardation among institutionalized patients. NMS and inv dup(15) have not been previously reported together. Their association should encourage clinicians to search for genetic markers for NMS.
 ...
PMID:Recurrent neuroleptic malignant syndrome associated with inv dup(15) and mental retardation. 199 19

A case of neuroleptic malignant syndrome is described in a 37-year-old man with mental retardation, hypomania and a history of recent hepatitis B infection. The NMS is reviewed and the potential importance of this iatrogenic emergency in mental handicap practice is emphasized.
 ...
PMID:Neuroleptic malignant syndrome with hypomania and mental retardation. 276 43

Neuroleptic malignant syndrome, an uncommon but potentially lethal complication of antipsychotic medication that has received little notice in the mental retardation literature, was reviewed. An analysis of 29 cases in which the condition appeared in individuals with mental retardation was also provided. Recommendations about reducing morbidity and mortality among members of this population, for whom neuroleptic use is common, were made.
 ...
PMID:Neuroleptic malignant syndrome and mental retardation: review and analysis of 29 cases. 810 96

Neuroleptic malignant syndrome (NMS) is a life-threatening complication of anti-psychotic treatment and can occur any time during the course of treatment. Since NMS can occur in any subject treated with anti-psychotic drugs, causing senously adverse side effects, prevention of NMS is one of the most important issues in clinical psychiatry. Although therapeutic guidelines for NMS have been proposed and gradually put in place, the pathogenesis has not been fully elucidated. Prevention of NMS consists of three approaches: removal of pathogenetic factors, understanding of initial symptoms and consideration of the administration of preventive drugs. Risk factors for NMS are inherited factors, individual factors and environmental factors. The overlapping of these factors might lead to fulminant NMS. These risk factors such as environmental factors are enumerated in DSM-IV. We meta-analyzed the case-control studies of the risk factors for NMS, because the evaluation of each risk factor has not been studied yet. The results were as follows: mental retardation, psychiatric manifestations such as agitation and excitement as individual factors. High dosage administration, rapid increase and parenteral administration of antipsychotic drugs are the drug factors. It is hopeful to give preventive care, such as precautionary measurement of autonomic dysfunction, and treatment to these groups at high risk for NMS.
 ...
PMID:[Studies of risk factors and preventive care for neuroleptic malignant syndrome]. 1724 Aug 42

ABSTRACT Neuroleptic malignant syndrome (NMS) is a potentially fatal disorder associated with the use of neuroleptics. Clinical research on NMS to date has focused exclusively on adults, but increasing numbers of juvenile cases have been reported. Two cases of juvenile NMS treated by the authors are discussed to demonstrate early warning signs, possible contributory factors, and effective treatment strategies. Forty-nine reported cases of NMS in children and adolescents are then reviewed in order to assess frequency, possible risk factors, predictors of poor outcome, and effective treatment. The most common diagnosis is schizophrenia (35%) followed by bipolar disease (12%), schizoaffective disorder (8%), and mental retardation (8%). Over half the reported cases involve treatment with high potency neuroleptics (57%), compared to only 14% with low potency neuroleptics. The death rate in patients 18 years or younger is 16%. In adolescent patients, the death rate is 13%; this rate increases to 27% in patients 12 years or younger. A recent adult study, by contrast, estimates a mortality rate of only 4%. We conclude that NMS in children, may be underdiagnosed, and that failure to diagnose may contribute to relatively high juvenile mortality rates.
 ...
PMID:Neuroleptic malignant syndrome in children and adolescents: two case reports and a warning. 1963 Jun 50

A 32-year-old female, with a history of secondarily-generalized convulsive epilepsy, mental retardation, and a psychiatric illness, developed neuroleptic malignant syndrome while receiving carbamazepine and amitriptyline concurrently. We hypothesize that the addition of amitriptyline to carbamazepine caused a decrease in the serum level of carbamazepine, resulting in NMS. We conclude that combination therapy with carbamazepine and amitriptyline should be avoided in patients who are predisposed to NMS. The purpose of this paper is to warn physicians against combination therapy with carbamazepine and tricyclic antidepressants which may be conducive to neuroleptic malignant syndrome in susceptible patients.
 ...
PMID:Neuroleptic malignant syndrome caused by a combination of carbamazepine and amitriptyline. 2295 86

Neuroleptic malignant syndrome (NMS) is a life-threatening emergency that is often seen as a complication of antipsychotic agents. It is characterized by a tetrad of motor, behavioral, autonomic, and laboratory abnormalities. We report a case of a 34-year-old man with a history of newly diagnosed Type 2 diabetes mellitus, mental retardation, and behavioral abnormalities who developed NMS after starting on antipsychotic agents. He presented with high temperature, muscle rigidity, tachycardia, and elevated blood pressure. After a week of hospital treatment in the general ward of a secondary care unit, he was discharged in a hemodynamically and mentally stable state.
...
PMID:Neuroleptic malignant syndrome. 2745 70